Biomarker of improved intestinal function
The invention disclosed herein demonstrates that that the adaptive process in the intestine can be tracked using plasma citrulline. It further demonstrates that plasma citrulline is of clinical utility as a biomarker for improvements in intestinal function.
1 . A method for monitoring improvements in intestinal function in an individual comprising the step of measuring levels of plasma citrulline in the individual over a period of time, wherein an increase in plasma citrulline is indicative of improvement in intestinal function.
2 . A method for monitoring the adaptive process of the intestine of an individual comprising the step of monitoring levels of plasma citrulline in the individual over a period of time, wherein an increase in plasma citrulline is indicative of improvement in intestinal function.
3 . A method according to claim 1 wherein the individual is undergoing treatment with an analogue of GLP-2.
4 . A kit for monitoring the adaptive process of the intestine of an individual by monitoring levels of plasma citrulline in the individual over a period of time comprising reagents and consumables together with instructions for their use.
5 . A method according to claim 3 comprising the steps:
a. determining the plasma citrulline level of the subject at a first time point;
b. administering the GLP-2 analogue to the subject; and
c. determining the plasma citrulline level at a second time point;
wherein an increased level of plasma citrulline at the second time point relative to the first time point is indicative of the efficacy of the treatment.
6 . A method for determining the efficacy of a test compound administered to a subject for the treatment of intestinal damage, comprising the steps:
a. determining the plasma citrulline level of the subject at a first time point;
b. administering the test compound to the subject; and
c. determining the plasma citrulline level at a second time point
wherein an increased level of plasma citrulline at the second time point relative to the first time point is indicative of the efficacy of the test compound.
7 . A method for monitoring the progress of a therapeutic regime designed to treat intestinal damage, comprising:
a. determining the plasma citrulline level of the subject at a first time point;
b. determining the plasma citrulline level at a second time point, wherein the therapeutic regime is followed by the subject between the first and second time points;
wherein an increased level of plasma citrulline at the second time point relative to the first time point is indicative of the efficacy of the treatment regime.